- Home
- SABS
as 07-26-2024 4:00pm EST
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SIOUX FALLS |
| Market Cap: | 26.3M | IPO Year: | N/A |
| Target Price: | $13.00 | AVG Volume (30 days): | 7.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.36 - $10.50 | Next Earning Date: | 08-19-2024 |
| Revenue: | $2,602,465 | Revenue Growth: | -79.48% |
| Revenue Growth (this year): | -56.95% | Revenue Growth (next year): | N/A |
Latest SAB Biotherapeutics Inc. News
SABS Breaking Stock News: Dive into SABS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
SAb Biotherapeutics Rebrands as SAB BIO
GlobeNewswire
a month ago
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
GuruFocus.com
a month ago
A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
Energy Global
a month ago
ANDRITZ to equip new Silvan hydropower plant in Türkiye
USA TODAY
a month ago
Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
Business Wire
a month ago
Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
Business Wire
a month ago
Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
GlobeNewswire
a month ago
SEALSQ to Launch Two New Quantum Resistant Chips
Compare SABS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SABS SAB Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.